April 28, 2021:
Cellanyx Publishes Paper on MVL/AI driven Test to Predict
Prostate Cancer Tumor Aggressiveness in Reviews in Urology journal.
December 19, 2018:
Cellanyx Publishes Results of Clinical Proof-of-Concept Study in the Urology.
October 8, 2018:
Cellanyx Publishes Results of Clinical Validation Study in Nature Biomedical Engineering.
September 12, 2017:
Cellanyx wins 1st place poster award at the 2nd International Prostate Cancer Symposium, held at Mt. Sinai Hospital.
June 15, 2017:
Cellanyx SAB Members Author Publication in Nature Precision Oncology
June 1, 2017:
Chander AC, Manak MS, Varsanik JS, Hogan BJ, Mouraviev V, Zappala SM, Sant GR, Albala DM (2017) “Rapid and Short Term ECM Mediated In Vitro Culturing of Tumor and Nontumor Human Primary Prostate Cells” Urology
September 28, 2016:
Presented at AdMeTech Foundation’s First Global Summit on Precision Diagnosis for Prostate Cancer, 2016.
May 11, 2016:
Abstract: Clinical Validation of a live-cell phenotypic biomarker – based diagnostic assay for the prediction of adverse pathology in Prostate Cancer.
Presented at AUA, 2016.
January 20, 2016:
Abstract: A Live Cell Microfluidics Device Utilizing Phenotypic Biomarkers for Prostate Cancer.
Presented at IPCU, 2016.
January 7, 2016:
Cellanyx Presents Latest Clinical Data in Poster Presentation at ASCO – GU Symposium, 2016
Abstract: A Live Cell Microfluidics Device Utilizing Phenotypic Biomarkers for Prostate Cancer.
Presented at ASCO-GU, 2016.
December 7, 2015:
October 30, 2015:
genitourinary cancer risk stratification.
BJUI Abstract presented at CURA Conference, 2015.
May 15, 2015:
Cellanyx Presents Latest Clinical Data in Poster Presentation at the Annual AUA Meeting
Abstract: A Novel Live Cell Microfluidic Diagnostic Using Phenotypic Biomarkers With Objective Algorithmic Analysis for Prostate Cancer Risk Stratification.
Presented at AUA, 2015.
April 22, 2015:
Abstract: A Novel Live Cell Diagnostic Platform Measuring Phenotypic Biomarkers Using Objective Algorithmic Analysis Enables Further Risk Stratification For Intermediate-Risk Prostate Cancer Patients.
Presented at AACR, 2015.
February 24, 2015:
Presented at ASCO Genitourinary Cancers Symposium, 2015.